MDM2 binding protein as a predictor of metastasis and a novel prognostic biomarker in patients with gastric cancer

• DOI: 10.3892/ol.2017.7031
• Publication Date: 2017-09-22T08:35:28Z
• Authors: Wei Wang; Zhong Chen; Jiejie Jin; Ziwen Long; Xiaowen Liu; Hong Cai; Ye Zhou; Hua Huang; Yanong Wang
• Keywords: Tissue microarray; Clinical Significance

MDM2 binding protein (MTBP) has been revealed to be involved in cancer progression and metastasis. However, the role clinical implication of MTBP expression gastric (GC) remains poorly understood. The present study aimed investigate clinicopathological significance prognostic determinant GC. level was examined cancerous matched adjacent noncancerous mucosa tissues by reverse transcription-quantitative polymerase chain reaction western blotting. levels were evaluated immunohistochemical analysis tissue microarrays for 352 patients, association between prognosis patients with GC investigated. Kaplan-Meier Cox's regression models used associations patients. results decreased mRNA (P=0.005) (P=0.001) tumor compared normal mucosa. associated gender (P=0.026), lymph node metastasis (P<0.001), distant (P=0.026) pathological tumor-node-metastasis stage (P<0.001). survival demonstrated that high exhibited longer times low levels. multivariate logistic independently presence [OR, 0.282; 95% confidence interval (CI), 0.161-0.494; P<0.001] (OR, 0.365; CI, 0.138-0.965; P=0.042). Furthermore, Cox significantly overall time recognized as an independent factor patient's survival. GC, suggesting may a predictive marker patient